Evidence for additional neurotensin receptor subtypes: Neurotensin analogs that distinguish between neurotensin-mediated hypothermia and antinociception

Brain Research

Volumn 792, Issue 2, 1998, Pages 246-252

  Tyler, Beth M ^a   Cusack, Bernadette ^a   Douglas, Christopher L ^a   Terrance Souder, ^a   Richelson, Elliott ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antinociception; Hypothermia; Neurotensin; Neurotensin receptor

Indexed keywords

2 [5 (2,6 DIMETHOXYPHENYL) 1 [4 [N (3 DIMETHYLAMINOPROPYL) N METHYLCARBAMOYL] 2 ISOPROPYLPHENYL] 1H PYRAZOL 3 YLCARBONYLAMINO]ADAMANTANE 2 CARBOXYLIC ACID; 2 [[1 (7 CHLORO 4 QUINOLINYL) 5 (2,6 DIMETHOXYPHENYL) 3 PYRAZOLYL]CARBONYLAMINO] 2 ADAMANTANECARBOXYLIC ACID; NEUROTENSIN; NEUROTENSIN 24; NEUROTENSIN 27; NEUROTENSIN 27 1; NEUROTENSIN DERIVATIVE; NEUROTENSIN RECEPTOR; NEUROTENSIN[8-13]; NT 27; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG POTENCY; HYPOTHERMIA; MALE; MOLECULAR CLONING; NONHUMAN; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; RAT; STEREOISOMERISM;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPOTHERMIA; MALE; MICE; NEUROTENSIN; NOCICEPTORS; PAIN; PYRAZOLES; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROTENSIN; SPECIES SPECIFICITY;

EID: 0032507690     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(98)00150-4     Document Type: Article

References (29)

1. Al-Rodhan N.R., Richelson E., Gilbert J.A., McCormick D.J., Kanba K.S., Pfenning M.A., Nelson A., Larson E.W., Yaksh T.L. Structure-antinociceptive activity of neurotensin and some novel analogues in the periaqueductal gray region of the brainstem. Brain Res. 557:1991;227-235.
2. Behbehani M.M., Pert A. A mechanism for the analgesic effect of neurotensin as revealed by behavioral and electrophysiological techniques. Brain Res. 324:1984;35-42.
3. Bissette G., Nemeroff C.B., Loosen P.T., Prange A.J. Jr., Lipton M.A. Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin. Nature. 262:1976;607-609.
4. Chalon P., Vita N., Kaghad M., Guillemot M., Bonnin J., Delpech B., Lefur G., Ferrara P., Caput D. Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Lett. 386:1996;91-94.
5. Clineschmidt B.V., McGuffin J.C., Bunting P.B. Neurotensin: antinocisponsive action in rodents. Eur. J. Pharmacol. 54:1979;129-139.
6. Cusack B., McCormick D.J., Pang Y.P., Souder T., Garcia R., Fauq A., Richelson E. Pharmacological and biochemical profiles of unique neurotensin 8-13 analogs exhibiting species selectivity, stereoselectivity, and superagonism. J. Biol. Chem. 270:1995;18359-18366.
7. Dubuc I., Costentin J., Terranova J.P., Barnouin M.C., Soubrie P., Le Fur G., Rostene W., Kitabgi P. The nonpeptide neurotensin antagonist, SR 48692, used as a tool to reveal putative neurotensin receptor subtypes. Br. J. Pharm. 112:1994;352-354.
8. Elliott P.J., Nemeroff C.B. Repeated neurotensin administration in the ventral tegmental area: effects on baseline and D-amphetamine-induced locomotor activity. Neurosci. Lett. 68:1986;239-244.
9. Goedert M., Pittaway K., Williams B.J., Emson P.C. Specific binding of tritiated neurotensin to rat brain membranes: characterization and regional distribution. Brain Res. 304:1984;71-81.
10. Gully D., Canton M., Boigegrain R., Jeanjean F., Molimard J.C., Poncelet M., Gueudet C., Heaulme M., Leyris R., Brouard A.et al. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc. Natl. Acad. Sci. U.S.A. 90:1993;65-69.
11. Gully D., Labeeuw B., Boigegrain R., Oury-Donat F., Bachy A., Poncelet M., Steinberg R., Suad-Chagny M.F., Santucci V., Vita N., Pecceu F., Labbe-Jullie C., Kitabgi P., Soubrie P., Le Fur G., Maffrand J.P. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. JPET. 280:1997;802-812.
12. Jensen T.S., Yaksh T.L. Comparison of the antinociceptive action of μ and δ opioid receptor ligands in the periaqueductal gray matter, medial and paramedial ventral medulla in the rat as studied by the microinjection technique. Brain Res. 372:1986;301-312.
13. 3H]neurotensin but with higher affinity. J. Neurochem. 50:1988;131-137.
14. Kasckow J., Nemeroff C.B. The neurobiology of neurotensin: focus on neurotensin-dopamine interactions. Regulatory Peptides. 36:1991;153-164.
15. Labbe-Jullie C., Dubuc I., Brouard A., Doulut S., Bourdel E., Pelaprat D., Mazella J., Martinez J., Rostene W., Costentin J.et al. In vivo and in vitro structure-activity studies with peptide and pseudopeptide neurotensin analogs suggest the existence of distinct central neurotensin receptor subtypes. JPET. 268:1994;328-336.
16. Mazella J., Botto J.-M., Guillemare E., Ckoppola T., Sarret P., Vincent J.-P. Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain. J. Neurosci. 16:1996;5613-5620.
17. 125I]Tyr3-neurotensin. Neuroscience. 22:1987;525-536.
18. O'Brien P.C. The appropriateness of analysis of variance and multiple-comparison procedures. Biometrics. 39:1983;787.
19. G. Paxinos, C. Watson, The Rat Brain in Stereotaxic Coordinates, 2nd edn., Academic Press, San Diego, 1986.
20. Pugsley T.A., Akunne H.C., Whetzel A.Z., Demattos S., Corbin A.E., Wiley J.N., Wustrow D.J., Wise L.D., Heffner T.G. Differential effects of the nonpeptide neurotensin antagonist, SR 48692, on the pharmacological effects of neurotensin agonists. Peptides. 16:1994;37.
21. Rossi G., Pan Y.X., Cheng J., Pasternak G.W. Blockade of morphine analgesia by an antisense oligodeoxynucleotide against the μ receptor. Life Sci. 54:1994;PL375-379.
22. Sadoul J.L., Mazella J., Amar S., Kitabgi P., Vincent J.P. Preparation of neurotensin selectively iodinated on the tyrosine 3 residue. Biological activity and binding properties on mammalian neurotensin receptors. Biochem. Biophys. Res. Commun. 120:1984;812-819.
23. 3H]neurotensin binding site in the rat brain. Arch. Pharmacol. 333:1986;400.
24. Smith D.J., Hawranko A.A., Monroe P.J., Gully D., Urban M.O., Craig C.R., Smith J.P., Smith D.L. Dose dependent pain-facilitaroy and -inhibitory actions of neurotensin are revealed by SR 48692, a nonpeptide neurotensin antagonist: influence on the antinociceptive effect of morphine. JPET. 282:1997;899-908.
25. Tanaka K., Masu M., Nakanishi S. Structure and functional expression of the cloned rat neurotensin receptor. Neuron. 4:1990;847-854.
26. Tyler B., Groshan K., Cusack B., Richelson E. In vivo studies with low doses of levocabastine and diphenhydramine, but not pyrilamine antagonize neurotensin-mediated antinociception. Brain Res. 787:1998;78-84.
27. N. Vita, P. Chalon, F. Donat, A. Bachy, M. Kaghad, M. Guillemot, O. Thurneyssen, J. Bonnin, B. Delpech, P. Soubrie, G. LeFur, D. Caput, P. Ferrara, Molecular cloning and characterization of a new human neurotensin binding site that recognizes levocabastine, Society for Neuroscience, General Meeting, Vol. 23, New Orleans, LA, 1997, pp. 158.10.
28. Vita N., Laurent P., Lefort S., Chalon P., Dumont X., Kaghad M., Gully D., Le Fur G., Ferrara P., Caput D. Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor. FEBS Lett. 317:1993;139-142.
29. Watson M., Isackson P.J., Makker M., Yamada M.S., Yamada M., Cusack B., Richelson E. Identification of a polymorphism in the human neurotensin receptor gene. Mayo Clin. Proc. 68:1993;1043-1048.